[1] Tursi A, Vetrone LM, Papa A. Anti-tnf-alpha Agents in Inflammatory Bowel Disease and Course of Covid-19. Inflamm Bowel Dis 2020;26:e73.

[2] Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, et al. Trials of Anti-tumour Necrosis Factor Therapy for Covid-19 are Urgently Needed. Lancet 2020;395:1407-9.

[3] Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk Factors for Severity and Mortality in Adult Covid-19 Inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110-8.

[4] Lv S, Han M, Yi R, Kwon S, Dai C, Wang R. Anti-tnfalpha Therapy for Patients with Sepsis: A Systematic Meta-analysis. Int J Clin Pract 2014;68:520-8.

[5] Samaan MA, Bagi P, Casteele NV, D’Haens GR, Levesque BG. An Update on Anti-Tnf Agents in Ulcerative Colitis. Gastroenterol Clin North Am 2014;43:479-94.

[6] Fausel R, Afzali A. Biologics in the Management of Ulcerative Colitis Comparative Safety and Efficacy of Tnf-alpha Antagonists. Ther Clin Risk Manag 2015; 11:63-73.

[7] Croft A, Walsh A, Doecke J, Cooley R, Howlett M, RadfordSmith G. Outcomes of Salvage Therapy for Steroidrefractory Acute Severe Ulcerative Colitis: Ciclosporin vs. Infliximab. Aliment Pharmacol Ther 2013;38:294-302.

[8] Brenner EJ, Ungaro RC, Colombel JF, Kappelman MD. Secure-ibd Database Public Data Update. http://www. covidibd.org. [Last accessed on 2020 Jul 13].

[9] Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in Critically Ill Patients in the Seattle Region Case Series. N Engl J Med 2020;382:2012-22.

[10] Shah ED, Farida JP, Siegel CA, Chong K, Melmed GY. Risk for Overall Infection with Anti-tnf and Anti-integrin Agents Used in Ibd: A Systematic Review and Metaanalysis. Inflamm Bowel Dis 2017;23:570-7.

[11] Minozzi S, Bonovas S, Lytras T, Pecoraro V, GonzalezLorenzo M, Bastiampillai AJ, et al. Risk of Infections Using Anti-tnf Agents in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: A Systematic Review and Meta-analysis. Expert Opin Drug Saf 2016;15:11-34.

[12] Ali M, McClean C, Zou Y, Goh J. Pth-076 Inflammatory Bowel Disease: The Consequences of Anti-tnf Therapy in the Elderly. Gut 2016;65:A256-7.

[13] Migliore A, Bizzi E, Lagana B, Altomonte L, Zaccari G, Granata M, et al. The Safety of Anti-tnf Agents in the Elderly. Int J Immunopathol Pharmacol 2009;22:415-26.

[14] Cheng D, Cushing KC, Cai T, Ananthakrishnan AN. Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients with Ulcerative Colitis: Patient-level Pooled Analysis of Data from Randomized Trials. Clin Gastroenterol Hepatol 2020;1:30615-7.

[15] de Jong ME, Smits LJ, van Ruijven B, den Broeder N, Russel M, Romkens TE, et al. Increased Discontinuation Rates of Anti-tnf Therapy in Elderly Inflammatory Bowel Disease Patients. J Crohns Colitis 2020;14:888-95.

[16] Lobaton T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and Safety of Anti-tnf Therapy in Elderly Patients with Inflammatory Bowel Disease. Aliment Pharmacol Ther 2015;42:441-51.

[17] Malaviya R, Laskin JD, Laskin DL. Anti-tnfalpha Therapy in Inflammatory Lung Diseases. Pharmacol Ther 2017;180:90-8.

[18] Abraham E, Anzueto A, Gutierrez G, Tessler S, Pedro GS, Wunderink R, et al. Double-blind Randomised Controlled Trial of Monoclonal Antibody to Human Tumour Necrosis Factor in Treatment of Septic Shock. Lancet 1998;351:929-33.

[19] Rodriguez-Lago I, de la Piscina PR, Elorza A, Merino O, de Zarate JO, Cabriada JL. Characteristics and Prognosis of Patients with Inflammatory Bowel Disease during the Sars-cov-2 Pandemic in the Basque Country (Spain). Gastroenterology 2020;159:781-3.